Vimarsana
Biggest News Aggregation in the World

Functional Cure News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Functional Cure. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Functional Cure Today - Breaking & Trending Today

FDA Grants Fast Track Designation for Bepirovirsen for Chronic Hepatitis B - Vimarsana News

FDA Grants Fast Track Designation for Bepirovirsen for Chronic Hepatitis B

The investigational antisense oligonucleotide’s designation is based on data from the phase 2b trials B-Clear and B-Sure.

Seraxis to Provide Oral Update on Its Pancreatic Organoid Candidate for Functional Cure of T1D at th - Vimarsana News

Seraxis to Provide Oral Update on Its Pancreatic Organoid Candidate for Functional Cure of T1D at th

Dr. William Rust will give an oral presentation on Seraxis’ proprietary technology for the production of therapeutic pancreatic organoids from pancreas-derived stem cells, as well as review initial diabetes model data of functional cure of Type 1 Diabetes. Seraxis’ presentation, entitled “Stem-cell Derived Islets fo...

Bioxytran (OTCMKTS: BIXT) Peer-Review Published Showing Functional Cure for COVID-19 - Vimarsana News

Bioxytran (OTCMKTS: BIXT) Peer-Review Published Showing Functional Cure for COVID-19

A new peer-reviewed medical journal article demonstrates a functional cure for COVID-19, influenza, and RSV. ProLectin-M also eliminates symptoms.

AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB - Vimarsana News

AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting - Vimarsana News

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...